Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (87) Filters Reset all × Publication × Alzheimer's disease × AMPK × Compound × FGF receptor-1 × GPR120 × NPY receptor × Search × Resource type Data presentation (1) Poster (58) Publication (87) 3D imaging video (2) Webinar (6) Category × Disease model (118) Cardiovascular disease (3) AngII mouse (0) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (1) DIO-PCK9-AAV mouse (0) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (18) Alzheimer's disease models (5) CNS activation (7) Drug distribution (1) Gene expression (0) Gene therapy (0) Parkinson's disease models (4) Diabetes (28) db/db mouse (14) Non-obese diabetic (NOD) mouse (3) ZDF rat (10) Inflammatory bowel disease (0) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (0) Idiopathic pulmonary fibrosis (0) BLEO-IPF mouse (0) Chronic BLEO-IPF mouse (0) HFD-BLEO-IPF mouse (0) Kidney disease (7) Acute kidney injury (1) Bilateral ischemia reperfusion injury (bIRI) mouse (0) Unilateral ischemia reperfusion injury (uIRI) mouse (1) Chronic kidney disease (2) Anti-GBM glomerulonephritis mouse (0) Adenine diet-induced (ADI) nephropathy mouse (1) Polycystic kidney disease (PCK) rat (0) Unilateral ureteral obstruction (UUO) mouse (1) 5/6 nephrectomy (Nx) rat (1) Diabetic kidney disease (5) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (3) ZSF-1 rat (0) Knock-out mouse models (6) Metabolic dysfunction-associated steatohepatitis (34) GAN DIO-MASH mouse (9) GAN DIO-MASH-HCC mouse (3) GAN ob/ob-MASH mouse (2) CDAA-HFD mouse (3) CDAA-HFD rat (3) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (12) Obesity (46) Bariatric surgery (10) DIO mouse (21) DIO rat (14) ob/ob mouse (8) Therapeutic Area (140) Alzheimer's disease (5) Alcoholic steatohepatitis (2) Cardiovascular disease (3) Chronic kidney disease (8) Cholangiopathy (1) Diabetes (52) Diabetic cardiomyopathy (1) Diabetic kidney disease (8) Hepatocellular carcinoma (4) Idiopathic pulmonary fibrosis (0) Inflammatory bowel disease (0) Metabolic dysfunction-associated steatohepatitis (41) Obesity (70) Parkinson's disease (4) Target (88) Alpha-synuclein (0) Autotaxin (0) Beta amyloid (0) Acetyl-CoA carboxylase (0) Amylin receptor (2) Angiotensin converting enzyme (ACE) (3) AMPK (1) ASBT (1) CB1 receptor (3) CCK receptor (4) D2 receptor (1) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (2) FXR (6) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (4) GLP-1 receptor (47) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (0) 5-HT2C receptor (1) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (2) Monoamine transporter (1) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (0) PICK1 (1) PPAR (11) PSD-95 (1) Renin–angiotensin system (1) Secretin receptor (1) SGLT-2 (3) TAAR1 (1) TGF-beta (0) TGR5 (0) THR-ß receptor (1) Y2 receptor (3) Compound (83) Aducanumab biosimilar (1) Adeno-associated virus (AAV)-mediated gene therapy (0) A3907 (1) Adrenomedullin (1) Alk5 inhibitor (0) ALT-801 (1) Amylin (1) Amylin receptor agonist (0) BLD-0409 (0) Bromocriptine (1) CHS-131 (1) Captopril (1) Cilofexor (0) Cotadutide (1) DA-1241 (0) Dapagliflozin (1) Dietary intervention (2) Exenatide (6) Elafibranor (5) Empagliflozin (3) Exendin-4 analogues (1) FGF21 (2) Firsocostat (0) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (2) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (0) GUBamy (0) GS-834356 (0) HSD17b13 inhibitor (0) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (2) INT-787 (0) Lanifibranor (2) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (2) Lorcaserin (1) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (7) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (1) Rimonabant (2) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (0) Semaglutide (8) SER140 (1) Setmelanotide (1) Sibutramine (2) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) Tirzepatide (0) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (147) 3D imaging (19) Adeno-associated virus (AAV)-mediated gene delivery (3) Atherosclerotic plaques (0) Beta-cell mass (11) Blood pressure (0) Body composition (10) Body weight (55) Blood biochemistry (33) Bariatric surgery (12) Bioinformatics (57) c-Fos activation (13) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (21) Drug distribution (1) Energy expenditure monitoring (3) Echocardiography (ECG) (2) Flow cytometry (0) Gut biopsy (6) Glomerular filtration rate (GFR) (3) Gastric emptying (3) Gut morphometry (9) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (27) Heart morphometry (1) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (49) Immunohistochemistry (IHC) (55) In situ hybridization (ISH) (13) Insulin tolerance test (ITT) (2) Kidney biopsy (1) Kidney morphometry (8) Lung functional test (0) Light sheet fluorescence microscopy (LSFM) (22) Liver biopsy (31) Liver morphometry (29) Lung biochemistry (0) Laser-capture microdissection (LCM) (8) Magnetic resonance imaging (MRI) (1) Microbiomics (5) Micro-computed tomography (micro-CT) (0) Neurobehavior (6) Next-generation sequencing (15) Nephrectomy (7) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (8) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (31) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (44) Single-cell RNA sequencing (2) Single-nucleus RNA sequencing (1) siRNA (1) StreaMLine (0) Surgery (8) Spirometry (0) Stereology (29) Stereotaxic injection (0) Ultrasound imaging (0) Urine biochemistry (4) Vasculature (1) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (0) Whole-brain in situ hybridization (0) Species (120) Hamster (1) Human (22) Mouse (84) Minipig (1) Non-human primate (3) Pig (2) Rat (27) Show (87) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × Publication × Alzheimer's disease × AMPK × Compound × FGF receptor-1 × GPR120 × NPY receptor × 87 resource library items found PublicationParaoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis PublicationIncreased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis PublicationTargeting postsynaptic glutamate receptor scaffolding proteins PSD-95 and PICK1 for obesity treatment PublicationProtection against overfeeding-induced weight gain is preserved in obesity but does not require FGF21 or MC4R PublicationDietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationTAAR1 Agonists Improve Glycemic Control, Reduce Body Weight and Modulate Neurocircuits Governing Energy Balance and Feeding PublicationSemaglutide reduces tumor burden in the GAN diet‑induced obese and biopsy‑confirmed mouse model of NASH‑HCC with advanced fibrosis PublicationWhole-brain activation signatures of weight-lowering drugs PublicationIdentification of GDF15 peptide fragments inhibiting GFRAL receptor signaling PublicationUncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging PublicationGLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity PublicationA3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans PublicationHepatoprotective effects of the long-acting FGF21 analogue PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationFASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models PublicationGIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior PublicationGIP affects hepatic fat and brown adipose tissue thermogenesis, but not white adipose tissue transcriptome in T1D PublicationNephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease PublicationStructurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease PublicationLEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men PublicationEffects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis PublicationHepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationLipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect PublicationPeptide-YY3-36/glucagon-like peptide-1 combination treatment of obese-diabetic mice improves insulin sensitivity associated with recovered pancreatic ß-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries PublicationTherapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650